Literature DB >> 17394681

A research agenda to promote the management of childhood tuberculosis within national tuberculosis programmes.

P R Donald1, D Maher, S Qazi.   

Abstract

Despite causing considerable mortality and morbidity, childhood tuberculosis (TB) is a neglected aspect of national tuberculosis programmes (NTPs), particularly in developing countries. A recently published World Health Organization (WHO) document, "Guidance for national tuberculosis programmes on the management of tuberculosis in children", addresses the effective management of children within NTPs. Taking into account this document and following a literature review, research priorities are identified to promote the integration of childhood tuberculosis into NTPs. The implications of human immunodeficiency virus (HIV) infection apply to all aspects of this agenda. The major priorities are: --The prospective evaluation of the incidence of childhood TB and the monitoring of programme performance with regard to childhood TB. A lot of data are already available within many programmes that could inform this process. --Study of the criteria to suspect and diagnose childhood TB using uniform criteria as defined in the Guidance document mentioned above. Evaluate new methodologies for this purpose. --Study the pharmacokinetics and toxicity of anti-tuberculosis drugs in children and the long-term outcome of the treatment of children. --Determine how many childhood contacts of adult pulmonary TB qualify for chemoprophylaxis in different communities. Study chemoprophylaxis for drug-resistant TB and chemoprophylaxis among certain groups of adolescents. --Document at what level children enter NTPs, the availability of qualified staff and their effectiveness in performing diagnostic investigations and ensuring quality care. Study the role of families as agents for DOTS, evaluate private sector participation in childhood TB management. --Document bacille Calmette-Guérin (BCG) immunisation complications and study management strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394681

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  22 in total

Review 1.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

2.  Childhood tuberculosis in Bhutan: profile and treatment outcomes.

Authors:  T Dendup; T Dorji; M E Edgnton; A M V Kumar; D Wangchuk; U Dophu; T Jamtsho; C Rinzin
Journal:  Public Health Action       Date:  2013-03-04

Review 3.  Diagnostic accuracy of nucleic acid amplification tests in urine for pulmonary tuberculosis: a meta-analysis.

Authors:  D Marangu; B Devine; G John-Stewart
Journal:  Int J Tuberc Lung Dis       Date:  2015-11       Impact factor: 2.373

4.  A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.

Authors:  Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jerphason Mecha; Jaclyn N Escudero; Thomas R Hawn; Grace John-Stewart
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

5.  Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy.

Authors:  S Bakeera-Kitaka; A Conesa-Botella; A Dhabangi; A Maganda; A Kekitiinwa; R Colebunders; D R Boulware
Journal:  Int J Tuberc Lung Dis       Date:  2011-08       Impact factor: 2.373

6.  Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study.

Authors:  Richard A Oberhelman; Giselle Soto-Castellares; Robert H Gilman; Luz Caviedes; Maria E Castillo; Lenka Kolevic; Trinidad Del Pino; Mayuko Saito; Eduardo Salazar-Lindo; Eduardo Negron; Sonia Montenegro; V Alberto Laguna-Torres; David A J Moore; Carlton A Evans
Journal:  Lancet Infect Dis       Date:  2010-07-23       Impact factor: 25.071

Review 7.  Priorities for tuberculosis research: a systematic review.

Authors:  Jamie Rylance; Madhukar Pai; Christian Lienhardt; Paul Garner
Journal:  Lancet Infect Dis       Date:  2010-11-01       Impact factor: 25.071

8.  Commentary: a targets framework: dismantling the invisibility trap for children with drug-resistant tuberculosis.

Authors:  Mercedes C Becerra; Soumya Swaminathan
Journal:  J Public Health Policy       Date:  2014-09-11       Impact factor: 2.222

9.  Setting priorities for a research agenda to combat drug-resistant tuberculosis in children.

Authors:  B Velayutham; D Nair; S Ramalingam; C M Perez-Velez; M C Becerra; S Swaminathan
Journal:  Public Health Action       Date:  2015-12-21

10.  The Delta fbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells.

Authors:  Muralidhar K Katti; Guixiang Dai; Lisa Y Armitige; Carlos Rivera Marrero; Sundarsingh Daniel; Christopher R Singh; Devin R Lindsey; Subramanian Dhandayuthapani; Robert L Hunter; Chinnaswamy Jagannath
Journal:  Cell Microbiol       Date:  2008-01-31       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.